Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome

J Pediatr Pharmacol Ther. 2022;27(8):695-702. doi: 10.5863/1551-6776-27.8.695. Epub 2022 Nov 17.

Abstract

Objective: To quantify the effect of early rescue surfactant administration techniques for preterm infants with respiratory distress syndrome (RDS) from a health care delivery system perspective.

Methods: A cost-consequence model was developed based on previously published literature to compare the health economic impact of implementing early surfactant administration strategies vs standard surfactant administration via endotracheal intubation and mechanical ventilation (MV).

Results: Early rescue surfactant treatment strategies are associated with a decrease in the number of patients requiring MV, cumulative MV days, and rate of neonatal complications. Total annual surfactant costs are higher than standard surfactant administration, but this is offset by savings in total hospital and complication costs.

Conclusions: This cost-consequence analysis suggests selective early rescue surfactant administration strategies are associated with a lower health care burden in premature infants with RDS.

Keywords: bronchopulmonary dysplasia; cost-consequence analysis; health economics; intubate surfactant extubate; less invasive surfactant administration; premature infants; respiratory distress syndrome.

Grants and funding

Disclosures. Financial support for this study was provided by Chiesi USA Inc. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. The content and results in the manuscript were approved by all authors and have not been subject to sponsor censorship. WY and IJ are employees of PRECISIONheor, which provides consulting services to the biopharmaceutical industry, including Chiesi USA Inc. PRECISIONheor has received professional fees for the development of the model from Chiesi USA Inc. MC, KD, BB, and DF are employees of Chiesi USA Inc, and they may have equity in Chiesi USA Inc. MM is a neonatologist at the Neonatal-Perinatal Medicine Division, Children's Hospital of Orange County, who provides consultancy service and received professional fees from Chiesi USA Inc.